Effect of Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in Chronic Spinal Cord Injury
Abstract
Severe bone loss commonly occurs in individuals with chronic spinal cord injury who are nonweight-bearing and leads to an increased risk of lower extremity fractures. This 12 month, multi-site, double-blind, randomized, placebo-controlled study evaluates the efficacy and safety of two interventions known to be anabolic to bone, parathyroid hormone and mechanical loading (provided as teriparatide and vibration, respectively) in 60 SCI individuals with low bone mass. At the end of the fourth year of this project, enrollment has been completed. 56 out of 60 participants completed year 1 of the study (retention rate of 93%); 25 participants who completed elected to begin a one year open-label extension of teriparatide therapy. No safety issues have arisen during the course of the study. Data from the first year of study are being finalized, and results regarding efficacy will only be available after database lock and subsequent analysis.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2014
- Accession Number
- ADA624307
Entities
People
- Thomas J Schnitzer
Organizations
- Northwestern University